A prospective, randomized, double-blind study of the tolerability of rifapentine 600, 900, and 1,200 mg plus isoniazid in the continuation phase of tuberculosis treatment

American Journal of Respiratory and Critical Care Medicine

Volumn 165, Issue 11, 2002, Pages 1526-1530

  Bock, Naomi N ^a,b,c,d,e   Sterling, Timothy R ^a,b,c,d,e   Hamilton, Carol D ^a,b,c,d,e   Pachucki, Connie ^a,b,c,d,e   Wang, Yong Cheng ^a,b,c,d,e   Conwell, Donna S ^a,b,c,d,e   Mosher, Ann ^a,b,c,d,e   Samuels, Mary ^a,b,c,d,e   Vernon, Andrew ^a,b,c,d,e  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c DUKE UNIVERSITY   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; RIFAPENTINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; LATENT PERIOD; MALE; MULTICENTER STUDY; MUSCLE WEAKNESS; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; STOMACH PAIN; TREATMENT OUTCOME; TUBERCULOSIS;

ADULT; AGED; ANTITUBERCULAR AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; ISONIAZID; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REFERENCE VALUES; RIFAMPIN; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 0036606533     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/rccm.200201-047OC     Document Type: Article

References (16)

1. Rifapentine and isoniazid in the continuation phase of treating pulmonary tuberculosis
2. Once-weekly rifapentine and isoniazid versus twice-weekly rifampin and isoniazid in the continuation phase of therapy for drug-susceptible pulmonary tuberculosis: A prospective, randomized clinical trial among HIV-negative persons
3. Development of rifapentine: The way ahead
4. US Public Health Service cooperative trial of three rifampin-isoniazid regimens in the treatment of pulmonary tuberculosis
5. Treatment of tuberculosis and tuberculosis infection in adults and children
6. Changing frequency of interim analysis in sequential monitoring
7. A multiple testing procedure for clinical trials
8. New antibacterial drugs for the treatment of mycobacterial disease in man
9. Antituberculosis activity of once-weekly rifapentine-containing regimens in mice. Long-term effectiveness with 6- and 8-month treatment regimens
10. Evaluation of an intensive intermittent-induction regimen and duration of short-course treatment for human immunodeficiency virus-related pulmonary tuberculosis
11. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid
12. Acquired rifamycin resistance in persons with advanced HIV disease being treated for active tuberculosis with intermittent rifamycin-based regimens
13. Effectiveness of once-weekly rifapentine and moxifloxacin regimens against Mycobacterium tuberculosis in mice